Methoxy polyethylene glycol-epoetin beta - Biologic Drug Details

Summary for methoxy polyethylene glycol-epoetin beta

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for methoxy polyethylene glycol-epoetin beta

Recent Clinical Trials for methoxy polyethylene glycol-epoetin beta

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Akebia Therapeutics	PHASE3
PT Kalbe Genexine Biologics	PHASE3
Genexine, Inc.	PHASE3

See all methoxy polyethylene glycol-epoetin beta clinical trials

Pharmacology for methoxy polyethylene glycol-epoetin beta

Physiological Effect	Increased Erythroid Cell Production
Established Pharmacologic Class	Erythropoiesis-stimulating Agent
Chemical Structure	Erythropoietin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for methoxy polyethylene glycol-epoetin beta Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for methoxy polyethylene glycol-epoetin beta Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Vifor (international) Inc.	MIRCERA	methoxy polyethylene glycol-epoetin beta	Injection	125164		2007-10-23	DrugPatentWatch analysis and company disclosures
Vifor (international) Inc.	MIRCERA	methoxy polyethylene glycol-epoetin beta	Injection	125164		2015-06-07	DrugPatentWatch analysis and company disclosures
Vifor (international) Inc.	MIRCERA	methoxy polyethylene glycol-epoetin beta	Injection	125164		2015-06-06	DrugPatentWatch analysis and company disclosures
Vifor (international) Inc.	MIRCERA	methoxy polyethylene glycol-epoetin beta	Injection	125164		2015-06-06	DrugPatentWatch analysis and company disclosures
Vifor (international) Inc.	MIRCERA	methoxy polyethylene glycol-epoetin beta	Injection	125164		2015-06-06	DrugPatentWatch analysis and company disclosures
Vifor (international) Inc.	MIRCERA	methoxy polyethylene glycol-epoetin beta	Injection	125164		2013-08-02	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for methoxy polyethylene glycol-epoetin beta Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Vifor (international) Inc.	MIRCERA	methoxy polyethylene glycol-epoetin beta	Injection	125164		2038-02-28	Patent claims search
Vifor (international) Inc.	MIRCERA	methoxy polyethylene glycol-epoetin beta	Injection	125164		2039-03-19	Patent claims search
Vifor (international) Inc.	MIRCERA	methoxy polyethylene glycol-epoetin beta	Injection	125164		2030-08-13	Patent claims search
Vifor (international) Inc.	MIRCERA	methoxy polyethylene glycol-epoetin beta	Injection	125164		2032-03-12	Patent claims search
Vifor (international) Inc.	MIRCERA	methoxy polyethylene glycol-epoetin beta	Injection	125164		2031-02-02	Patent claims search

International Patents for methoxy polyethylene glycol-epoetin beta

Country	Patent Number	Estimated Expiration
Israel	73785
Czech Republic	281542
Japan	H0435159
Japan	2002045191
China	1063969
Greece	852245

Methoxy polyethylene glycol-epoetin beta Market Analysis and Financial Projection

Last updated: February 15, 2026

What Are the Market Dynamics for Methoxy Polyethylene Glycol-Epoetin Beta?

Methoxy polyethylene glycol-epoetin beta (brand name Mircera) is a long-acting erythropoiesis-stimulating agent (ESA). It received approval from the European Medicines Agency (EMA) in 2007 and is marketed primarily in Europe, with limited availability in other regions. The drug is used to treat anemia caused by chronic kidney disease (CKD), both in dialysis-dependent and non-dialysis patients.

Market Size and Growth Drivers
The global anemia treatment market, projected to reach approximately USD 6.2 billion by 2027, includes ESAs like Mircera. Factors influencing growth include rising CKD prevalence, advances in dialysis technology, and increasing awareness of anemia management. The global CKD population is estimated to grow at a compound annual growth rate (CAGR) of 4.3% from 2020 to 2030, driven by aging populations and increased incidence of diabetes and hypertension.

Competitive Landscape
Mircera competes chiefly with other ESAs, including epoetin alfa (Epogen, Procrit), darbepoetin alfa (Aranesp), and biosimilars. Biosimilar ESAs have entered markets in Europe and the US, generating price competition and market share shifts. Notably, Amgen, Roche, and Janssen Pharmaceuticals have significant presence with their epoetin and darbepoetin products.

Regulatory Environment
Europe remains the primary market for Mircera, with regulatory approval based on its longer dosing intervals (often every two to four weeks) versus conventional ESAs requiring weekly or biweekly administration. US approval was not granted, limiting market expansion in North America. Countries with strict regulations on ESA use and pricing policies influence global uptake.

Pricing and Reimbursement Trends
Mircera commands premium pricing due to its extended dosing schedule, which reduces administration frequency and healthcare visits. However, reimbursement varies by country; in highly regulated markets with cost containment policies, price pressure limits margins. In emerging markets, price sensitivity hampers sales expansion.

What Is the Financial Trajectory for Methoxy Polyethylene Glycol-Epoetin Beta?

Historical Revenue and Sales Data
Since its launch in Europe around 2007, Mircera has shown a steady but competitive revenue trajectory. In 2020, its estimated global sales ranged between USD 250 million and USD 350 million, primarily in Europe, according to IQVIA data. Year-over-year growth averaged approximately 3–4% before the advent of biosimilars.

Impact of Biosimilars and Market Share
Biosimilar ESAs entered European markets starting in 2018, exerting downward pressure on Mircera's price and sales. Of particular note, biosimilars for epoetin alfa and darbepoetin alfa received approval earlier and have expanded access, often at 30–50% lower prices. This competition has limited Mircera's growth potential and led to sales stagnation in some regions.

Future Revenue Projections
Projections for 2023-2027 suggest a compounded annual decline of 2–4% in mature markets due to biosimilar competition. However, niche growth in emerging markets, where biosimilar adoption is slower, may offset declines somewhat. Market expansion strategies, including new indications (e.g., anemia in cancer patients) and geographic diversification, could alter projections.

Research and Development Outlook
No recent data indicates significant pipeline activity for Mircera in new indications. The focus remains on optimizing existing use cases and expanding access in lower-income countries through partnership or licensing arrangements.

Financial Risks and Opportunities
Pricing pressures and regulatory changes pose risks to revenue. Conversely, potential voluntary licensing agreements and biosimilar integration may provide new revenue streams. Companies investing in biosimilar ESA development aim to undercut Mircera and similar products, accelerating market share erosion.

Summary of Key Market and Financial Data

Aspect	Detail
Primary Market	Europe (main), limited elsewhere
Launch Year	2007 (EMA approval)
2020 Sales	USD 250–350 million (globally)
Growth Rate (pre-biosimilar)	3–4% annually until 2018
Biosimilar Impact	Volume growth slowed from 2018 onwards
Future Decline Rate	2–4% CAGR in mature markets (2023–2027)
Price Premium	Extended dosing schedule commands higher price in Europe

Key Takeaways

• Mircera primarily markets in Europe, with limited presence elsewhere.
• The presence of biosimilar ESAs constrains revenues due to pricing competition.
• Long-term growth prospects depend on geographic diversification and new indications.
• Revenue in mature markets is likely to decline amid biosimilar market penetration.
• Emerging markets offer potential for revenue expansion with lower competition barriers.

FAQs

1. How does methoxy polyethylene glycol-epoetin beta differ from other ESAs?
It has a longer half-life, allowing less frequent dosing (every two to four weeks), which improves patient convenience and reduces healthcare visits compared to traditional ESAs like epoetin alfa.

2. What factors influence Mircera’s market share?
Regulatory approvals, biosimilar competition, pricing policies, and physician prescribing habits impact its market share. Biosimilars have decreased Mircera's share in Europe since 2018.

3. Are there any upcoming regulatory changes affecting Mircera?
European authorities maintain high standards, but ongoing policies on biosimilar substitution and reimbursement could influence sales. No significant regulatory actions anticipated in the short term.

4. What are the main revenue risks for Mircera?
Introduction and aggressive pricing of biosimilar ESAs, patent expirations, and tighter reimbursement policies limit revenue potential.

5. Can Mircera expand into new indications?
Currently, no new indications are under active clinical development. Expansion depends on successful trials in anemia related to cancer or other chronic diseases.

---

Citations
[1] IQVIA. "Global Oncology and Hematology Market Data." 2021.
[2] European Medicines Agency. "Mircera (methoxy polyethylene glycol-epoetin beta): Summary of Product Characteristics." 2007.
[3] MarketWatch. "Anemia Treatment Market Size, Share & Growth." 2022.
[4] EvaluatePharma. "2021 World Preview: Outlook to 2026." 2021.